Anesthesia

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 171 person Asked by .

bookmark_add

Definition, activation criteria, and viscoelastic-guided (TEG/ROTEM) resuscitation targets; metabolic/electrolyte/thermal complications; antifibrinolytics/PCC; TACO vs TRALI.

description Clinical Response

"

Q17 · PAPER III · 10 MARKS

Massive Transfusion Protocol in Polytrauma with Hemorrhagic Shock

PGIMER · PAPER III — CRITICAL CARE, TRAUMA, RESUSCITATION & EMERGENCY [10 MARKS]

Definition, activation criteria, and viscoelastic-guided (TEG/ROTEM) resuscitation targets; metabolic/electrolyte/thermal complications; antifibrinolytics/PCC; TACO vs TRALI.

⚙ Core Concept

Modern MTP has shifted from ""1:1:1 ratio-driven"" empiric resuscitation toward viscoelastic-guided, goal-directed component therapy, recognizing trauma-induced coagulopathy is complex and multifactorial rather than simply dilutional.

A. Definition & Activation CriteriaHigh-Yield

Definition Type	Criteria
Classic	Transfusion of >=10 units PRBC in 24h, OR >=4 units in 1h with ongoing need
Functional	Replacement of one blood volume in 24h, or 50% in 3h

Activation scores: ABC score (penetrating mechanism, positive FAST, SBP<=90, HR>=120; score>=2 predicts need). Shock Index (HR/SBP>1.0). Clinical gestalt should prompt early activation regardless of formal score.

B. Viscoelastic-Guided (TEG/ROTEM) Resuscitation TargetsHigh-Yield

Parameter	Reflects	Abnormal -> Intervention
R-time/CT	Time to initial clot formation	Prolonged -> FFP
K-time/CFT, Angle	Rate of clot strengthening (fibrinogen)	Prolonged/low -> cryoprecipitate/fibrinogen concentrate
MA/MCF	Overall clot strength (platelets+fibrinogen)	Low -> platelets or fibrinogen/cryoprecipitate
LY30/ML	Fibrinolytic activity	Elevated -> tranexamic acid; very low = fibrinolysis shutdown, avoid more antifibrinolytic

C. Metabolic, Electrolyte & Thermal Complications4 marks

Complication	Mechanism	Management
Hypocalcemia	Citrate chelates ionized calcium	Monitor/replace proactively
Hyperkalemia	K+ leaks from stored RBCs	Monitor, treat if significant
Hypothermia	Cold products + exposure	Blood warmers, active warming
Metabolic acidosis	Hypoperfusion + citrate + saline	Address perfusion primarily
Dilutional coagulopathy	Large RBC/crystalloid volumes	Balanced/viscoelastic-guided transfusion
Hypomagnesemia	Citrate chelation	Monitor and replace

The ""Lethal Triad""

Hypothermia + Acidosis + Coagulopathy - each worsens the other two, a self-perpetuating cycle that MTP/damage control resuscitation is designed to interrupt early.

D. Antifibrinolytics & PCC3 marks

TXA: 1g IV loading over 10 min + 1g infusion over 8h, within 3 hours of injury (CRASH-2). Benefit is time-dependent - beyond 3h, no benefit/possible harm.

PCC: concentrated factors II,VII,IX,X - rapid VKA reversal; faster/lower volume than FFP; caution re: thrombotic risk.

E. TACO vs TRALI3 marks

Feature	TACO	TRALI
Mechanism	Hydrostatic volume overload	Immune-mediated donor antibody/leukocyte reaction
Onset	During/within 6h, often rapid	Within 6h, often 1-2h
Blood pressure	Hypertension common	Hypotension common
BNP	Elevated	Normal/near-baseline
Chest X-ray	Cardiomegaly, effusions	Bilateral infiltrates, no cardiomegaly (ARDS-like)
Response to diuretics	Improves	No improvement

💬 Viva Corner

Q. Why has viscoelastic testing replaced fixed-ratio (1:1:1) transfusion?

Trauma-induced coagulopathy is heterogeneous - fixed ratios risk under- or over-treating the actual defect; TEG/ROTEM allows real-time, patient-specific, goal-directed therapy.

Q. Why is TXA timing so critical?

CRASH-2 showed mortality benefit within 3 hours, with greatest benefit even earlier; beyond 3 hours there was no benefit and a signal of possible harm.

★ Examiner's Pearl

Quote the CRASH-2 TXA dosing/timing exactly (1g bolus + 1g over 8h, within 3h). Give a clear TACO vs TRALI comparison. Mention ""fibrinolysis shutdown"" as a distinct phenotype.

References

CRASH-2 Collaborators. Lancet 2010;376:23-32. Holcomb JB et al. JAMA 2015;313:471-482.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 172 person Asked by .

bookmark_add

Clinical criteria and legal framework for brain death determination per THOA (India); comprehensive management of a brain-dead organ donor to optimize multiorgan yield.

description Clinical Response

"

Q18 · PAPER III · 10 MARKS

Brain Death Determination (THOA Guidelines) & Brain-Dead Organ Donor Management

AIIMS/PGIMER · PAPER III — CRITICAL CARE, TRAUMA, RESUSCITATION & EMERGENCY [10 MARKS]

Clinical criteria and legal framework for brain death determination per THOA (India); comprehensive management of a brain-dead organ donor to optimize multiorgan yield.

⚙ Core Concept

Brain death is the complete and irreversible cessation of all brain and brainstem function, legally equivalent to death under India's THOA (1994, amended 2011/2014). Once declared, focus shifts entirely to active multiorgan donor optimization.

A. Clinical Criteria for Brain Death (THOA Framework)High-Yield

Preconditions: known cause of irreversible brain injury; exclusion of reversible causes (hypothermia, severe metabolic/endocrine disturbance, drug/NMB effect, profound uncorrected hypotension).

Reflex Tested	Method/Expected Absence
Pupillary light	Fixed, mid-to-dilated, no response bilaterally
Corneal	No blink to corneal stimulation
Oculocephalic (doll's eye)	No eye movement with head rotation (if C-spine cleared)
Vestibulo-ocular (cold caloric)	No nystagmus with ice-water irrigation
Gag	No response to pharyngeal stimulation
Cough	No response to tracheal suctioning
Motor response to pain	None in cranial nerve distribution (spinal reflexes may persist)
Apnea test	No respiratory effort with PaCO2 rising to >=60 mmHg (or >=20 above baseline); performed last

Legal/Procedural Framework Under THOA

Two separate examinations by a panel of 4 designated doctors, none part of the transplant team. Two sets of testing commonly ~6 hours apart. Both must independently confirm absent brainstem reflexes and positive apnea test. Time of death = time of second (confirmatory) test. Ancillary tests (EEG, CBF studies) not mandatory unless clinical testing is equivocal.

B. Comprehensive Brain-Dead Donor ManagementHigh-Yield

System	Goal	Management
Hemodynamic	MAP>=60-65, SBP>100	Judicious fluids; vasopressin often first-line
Diabetes insipidus	UOP<3-4 mL/kg/hr, normonatremia	DDAVP or vasopressin infusion; monitor Na closely
Endocrine (hormonal resuscitation)	Improve stability/organ function	High-dose methylprednisolone; T3/T4; insulin infusion
Temperature	Normothermia	Active warming - hypothalamic thermoregulation lost
Respiratory	Lung-protective ventilation	Low Vt, PEEP, minimize FiO2, bronchial hygiene
Glycemic control	140-180 mg/dL	Insulin infusion
Coagulation	Correct DIC risk	FFP/platelets/cryoprecipitate as guided

The ""Autonomic Storm"" then Hormonal Collapse

Initial catecholamine surge (severe HTN, tachycardia) followed by progressive hypothalamic-pituitary failure - DI, vasomotor collapse, adrenal/thyroid deficiency. Donor management must anticipate this cascade.

💬 Viva Corner

Q. Why must the apnea test be performed last?

It carries the highest risk of hypoxia/hypotension/arrhythmia during testing; performing it last ensures other reflexes are confirmed absent first, and ancillary tests can substitute if apnea testing is unsafe.

Q. Why is vasopressin often preferred over high-dose noradrenaline in donor management?

Brain-dead donors frequently develop DI from lost ADH secretion, so vasopressin provides dual antidiuretic + vasopressor benefit with less intense peripheral/splanchnic vasoconstriction, better preserving organ perfusion.

★ Examiner's Pearl

Explicitly state the THOA requirement of two examinations by a panel of four doctors, separated by the standard interval, none from the transplant team. Frame donor management around the autonomic-storm-to-hormonal-collapse narrative.

References

Transplantation of Human Organs and Tissues Act, 1994 (amended 2011, Rules 2014), Government of India. Kotloff RM et al. Crit Care Med 2015;43:1291-1325.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 173 person Asked by .

bookmark_add

Diagnosis, staging, and comprehensive ICU management of AKI following cardiac surgery; modern consensus criteria for initiating CRRT.

description Clinical Response

"

Q20 · PAPER III · 10 MARKS

Acute Kidney Injury Following Cardiac Surgery — Diagnosis, Staging & CRRT

PGIMER · PAPER III — CRITICAL CARE, TRAUMA, RESUSCITATION & EMERGENCY [10 MARKS]

Diagnosis, staging, and comprehensive ICU management of AKI following cardiac surgery; modern consensus criteria for initiating CRRT.

⚙ Core Concept

Cardiac surgery-associated AKI is multifactorial - CPB-related hemodilution/inflammation, non-pulsatile flow/hypoperfusion, hemolysis-related nephrotoxicity, and embolic phenomena. Even mild AKI (KDIGO Stage 1) is independently associated with increased mortality.

A. Diagnosis & Staging — KDIGO CriteriaHigh-Yield

KDIGO Stage	Serum Creatinine	Urine Output
Stage 1	1.5-1.9x baseline, OR >=0.3 mg/dL rise in 48h	<0.5 mL/kg/hr for 6-12h
Stage 2	2.0-2.9x baseline	<0.5 mL/kg/hr for >=12h
Stage 3	3.0x baseline, OR >=4.0 mg/dL, OR RRT initiated	<0.3 mL/kg/hr for >=24h, OR anuria >=12h

Diagnosis requires only ONE criterion; stage by whichever indicates more severe injury. Risk factors: pre-existing CKD/diabetes/age, prolonged CPB/cross-clamp time, hemodilution, hemolysis, non-pulsatile flow, embolic phenomena, nephrotoxin exposure, low cardiac output.

Diagnostic Workup

Serial creatinine trend, hourly urine output, urinalysis/microscopy, fractional excretion, novel biomarkers (NGAL, cystatin C, TIMP-2xIGFBP7), renal ultrasound if needed, hemodynamic/echo assessment.

B. Comprehensive ICU Management5 marks

Domain	Management Principles
Hemodynamic optimization	Maintain MAP>=65; optimize cardiac output; avoid hypovolemia AND overload
Fluid management	Balanced/restrictive once resuscitated; guided by dynamic assessment
Nephrotoxin avoidance	Minimize NSAIDs/aminoglycosides/repeat contrast; dose-adjust renally-cleared drugs
Diuretics	For fluid management only - do NOT prevent progression or aid recovery
Glycemic control	Avoid hyper- and hypoglycemia
Electrolyte management	Treat hyperkalemia, acidosis, hyperphosphatemia
Avoid further insults	Treat sepsis promptly, avoid hypotensive episodes

KDIGO Bundle Approach

Discontinue nephrotoxic agents, optimize volume/perfusion pressure, consider functional hemodynamic monitoring, monitor creatinine/urine output, avoid hyperglycemia, consider alternatives to radiocontrast.

C. Modern Consensus Criteria for Initiating CRRT5 marks

Trial	Key Finding
AKIKI	No mortality benefit with early vs delayed RRT initiation absent emergency indications
ELAIN	Suggested benefit with early initiation in a surgical/cardiac population - conflicting with AKIKI
STARRT-AKI	No significant 90-day mortality difference; accelerated strategy had MORE adverse events

Current consensus (post-STARRT-AKI): a ""watchful-waiting"" strategy - initiate based on absolute indications or clear deterioration rather than routine early initiation. CRRT (vs IHD) preferred in hemodynamically unstable patients due to gentler, continuous fluid/solute removal.

AEIOU — Absolute (Emergency) Indications

Acidosis (severe, refractory) · Electrolyte imbalance (refractory hyperkalemia) · Intoxication (dialyzable toxins) · Overload (refractory fluid overload) · Uremia (encephalopathy, pericarditis, bleeding).

💬 Viva Corner

Q. Creatinine 0.9->1.5 mg/dL with urine output 0.4 mL/kg/hr for 8h post-cardiac surgery - what KDIGO stage?

Stage 1 - creatinine is 1.67x baseline (within 1.5-1.9x range) and urine output also meets Stage 1 criteria (<0.5 mL/kg/hr for 6-12h).

Q. Why has ""early CRRT initiation"" fallen out of favor?

STARRT-AKI (large multinational RCT) found no mortality benefit from accelerated initiation vs standard criteria-based approach, with MORE adverse events in the accelerated arm.

★ Examiner's Pearl

Write out the full KDIGO staging table with exact ratios/thresholds. Quote the AEIOU mnemonic. Name the STARRT-AKI trial and its no-benefit conclusion explicitly.

References

KDIGO Clinical Practice Guideline for AKI (Kidney Int Suppl 2012;2:1-138). STARRT-AKI Investigators. N Engl J Med 2020;383:240-251.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 174 person Asked by .

bookmark_add

Architectural safety features and integrated safety mechanisms; electronic hypoxic guards, active scavenging systems, and decoupling of fresh gas flow.

description Clinical Response

"

Q21 · PAPER IV · 10 MARKS

Architectural Safety Features of Modern Anesthesia Workstations

AIIMS · PAPER IV — RECENT ADVANCES, TECHNOLOGY & EQUIPMENT [10 MARKS]

Architectural safety features and integrated safety mechanisms; electronic hypoxic guards, active scavenging systems, and decoupling of fresh gas flow.

⚙ Core Concept

Modern anesthesia workstations are engineered around multiple, layered, independent safety systems - each addressing a specific historically-documented failure mode. The shift from purely mechanical/pneumatic safeguards to integrated electronic monitoring is the most significant recent advance.

A. Gas Supply & Hypoxic Guard Safety Systems

Feature	Mechanism
Pin Index Safety System (PISS)	Unique pin configuration prevents wrong-cylinder attachment
Diameter Index Safety System (DISS)	Non-interchangeable, gas-specific pipeline connections
Color coding	Gas-specific colors - visual, supplementary safeguard
Mechanical hypoxic guard	Chain-linked O2-N2O valves, physically maintains >=25% O2
Electronic hypoxic guard	Continuously monitors delivered O2, auto-adjusts/alarms below threshold
Oxygen failure-protection devices	Auto cut-off N2O supply if O2 pressure falls
Oxygen failure alarm	Battery-backed, independent of mains power

B. Vaporizer & Agent Delivery Safety

Agent-specific keyed filling systems prevent mis-filling
Vaporizer interlock system prevents simultaneous engagement of >1 vaporizer
Inline gas analyzers identify agent and cross-check dial setting

C. Electronic Hypoxic Guard — Detailed MechanismHigh-Yield

Mechanical vs Electronic Hypoxic Guard

The mechanical guard only protects the fixed O2-N2O ratio via physical linkage. Electronic systems use real sensors with microprocessor control, manage complex gas scenarios, dynamically maintain safe FiO2, and integrate with the broader alarm system.

D. Active Scavenging SystemsHigh-Yield

Component	Function
Gas collecting assembly	Connects to APL valve/ventilator exhaust
Transfer tubing	Color-coded, distinct from breathing circuit tubing
Interface (active/passive)	Active uses wall suction with pressure-relief valves; passive relies on positive pressure venting

Active Scavenging Hazard — Negative Pressure

Suction could theoretically apply excessive negative pressure to the patient circuit; positive AND negative pressure relief valves in the interface prevent this.

E. Decoupling of Fresh Gas FlowHigh-Yield

Fresh Gas Decoupling — Why It Matters

In older designs, fresh gas entering during inspiration added directly to the delivered tidal volume, making it vary unpredictably with FGF. A decoupling valve diverts fresh gas away from the circuit during inspiration to a reservoir, so set tidal volume is delivered independent of FGF - critical for accurate volume-controlled ventilation, especially at low flows.

💬 Viva Corner

Q. Key advantage of an electronic vs mechanical hypoxic guard?

Mechanical only addresses a fixed O2-N2O ratio via physical linkage; electronic systems use real sensors to continuously monitor actual delivered O2 and integrate with the broader alarm system for more flexible protection.

Q. Why is fresh gas decoupling important, especially for low-flow anesthesia?

Without decoupling, FGF added directly to delivered tidal volume during inspiration causes unpredictable actual Vt when FGF changes mid-case; decoupling ensures the set Vt is delivered regardless of FGF.

★ Examiner's Pearl

Explicitly contrast mechanical vs electronic hypoxic guard mechanisms. Explain fresh gas decoupling with a clear ""why it matters"" framing rather than just naming it.

References

Dorsch JA, Dorsch SE. Understanding Anesthesia Equipment, 6th Ed Ch4-9. Eisenkraft JB, Sherman E. Miller's Anesthesia 9th Ed Ch26.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 175 person Asked by .

bookmark_add

Critical evaluation of depth-of-anesthesia monitoring; mathematical principles, clinical limitations, and utility in preventing intraoperative awareness.

description Clinical Response

"

Q22 · PAPER IV · 10 MARKS

Depth of Anesthesia Monitoring — BIS vs Patient State Index vs Spectral Entropy

AIIMS/PGIMER · PAPER IV — RECENT ADVANCES, TECHNOLOGY & EQUIPMENT [10 MARKS]

Critical evaluation of depth-of-anesthesia monitoring; mathematical principles, clinical limitations, and utility in preventing intraoperative awareness.

⚙ Core Concept

All processed-EEG depth-of-anesthesia monitors are proprietary, manufacturer-derived statistical indices built from raw frontal EEG - not direct measures of consciousness - each using different mathematical approaches, all sharing vulnerability to artifact and agent-specific calibration issues.

A-C. Mathematical Principles

Monitor	EEG Montage	Core Mathematical Basis	Range/Target
BIS	Frontal (fewer channels)	Bispectral analysis + power spectral + time-domain features	0-100; target 40-60
Patient State Index (PSI)	4-channel quadrant (bifrontal+temporo-occipital)	Anterior-posterior EEG gradient analysis	0-100; target ~25-50
Spectral Entropy	Frontal, 2-3 electrodes	Shannon entropy (signal irregularity) applied to power spectrum	SE 0-91 / RE 0-100; target SE~40-60

State Entropy (SE, 0.8-32 Hz, cortical only) vs Response Entropy (RE, 0.8-47 Hz, includes frontal EMG). A widening RE-SE gap indicates EMG/muscle activity - suggesting inadequate analgesia/light anesthesia even if SE looks adequate.

E. Clinical Limitations — Common to All Processed-EEG MonitorsHigh-Yield

Shared Limitations

EMG/artifact interference (cautery, movement, shivering) can falsely elevate the index. Agent-specific calibration issues - unreliable with ketamine (paradoxically high values), N2O, dexmedetomidine. Inter-individual variability (age extremes). Inherent processing lag (~15-30s). Landmark trials (B-Aware, BAG-RECALL, B-Unaware) show these monitors reduce but do not eliminate awareness risk.

F. Utility in Preventing Intraoperative Awareness

Most beneficial as part of a protocol-driven approach in high-risk populations: TIVA-based anesthesia, neuromuscular-blocked patients, cardiac/trauma surgery, prior awareness history. Should be considered an adjunct to, not a replacement for, sound clinical judgment and end-tidal agent monitoring.

💬 Viva Corner

Q. Why might BIS show a paradoxically high value with ketamine?

Ketamine produces increased high-frequency (gamma) EEG activity unlike GABAergic agents used to validate these algorithms, so the monitor can misinterpret this as a lighter plane than clinically present.

Q. What did the B-Unaware trial demonstrate?

BIS-guided and end-tidal anesthetic gas-guided protocols had similarly low awareness rates, suggesting any structured protocol-driven approach - not BIS specifically - may be the key factor.

★ Examiner's Pearl

Name the specific mathematical basis distinguishing each monitor. The RE-SE gap and its meaning is frequently tested. Cite B-Unaware/B-Aware/BAG-RECALL to show these monitors reduce but do not eliminate awareness.

References

Avidan MS et al. N Engl J Med 2008;358:1097-1108 (B-Aware). Viertio-Oja H et al. Acta Anaesthesiol Scand 2004;48:154-161.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 176 person Asked by .

bookmark_add

Concept of TCI in TIVA; comparison of pharmacokinetic properties and operational differences between Marsh and Schnider models for propofol.

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

"

Q24 · PAPER IV · 10 MARKS

Target-Controlled Infusion in TIVA — Marsh vs Schnider Models

AIIMS · PAPER IV — RECENT ADVANCES, TECHNOLOGY & EQUIPMENT [10 MARKS]

Concept of TCI in TIVA; comparison of pharmacokinetic properties and operational differences between Marsh and Schnider models for propofol.

⚙ Core Concept

TCI systems use a computer-controlled pump running a population pharmacokinetic model to achieve/maintain a clinician-set target concentration. Marsh and Schnider differ in derived population and covariates, producing clinically meaningful dosing differences in non-average patients.

A. Concept of TCI

Clinician sets a target (plasma or effect-site) -> a 3-compartment PK model (central + 2 peripheral) with population rate constants -> pump calculates/adjusts infusion in real time.

Plasma-targeting: achieves plasma concentration quickly, may overshoot effect-site before equilibration.

Effect-site targeting: uses ke0 to drive faster brain equilibration, more closely tracking clinically relevant concentration.

B & C. Marsh vs Schnider Models

Parameter	Marsh	Schnider
Population studied	Small group, weight-based	Larger, more diverse, wider age range
Covariates used	Weight only - no age	Age, height, weight, lean body mass (LBM)
Central compartment (V1)	Scales with weight	Fixed value regardless of weight
Rate constants	Fixed, not age-adjusted	Age-adjusted
ke0	Relatively slow	Faster effect-site equilibration

D. Key Operational DifferencesHigh-Yield

Feature	Marsh	Schnider
Age as covariate	Not incorporated (standard version)	Explicitly incorporated
Behavior in obese patients	Overestimates dose (V1 scales with total weight)	Better suited - LBM-based scaling
Behavior in elderly	No age adjustment - relative overdose risk if unadjusted	Automatically reduces requirement with age
Onset feel	Larger initial bolus feel, more pronounced hypotension risk	Gentler, more gradual onset

Shared Limitations

Neither model is validated for children (separate Paedfusor/Kataria models exist). Both are population-derived - individual pharmacokinetics can deviate, particularly in critical illness or organ dysfunction. Predicted concentrations are model estimates, not measured levels.

💬 Viva Corner

Q. Why might Marsh lead to relative overdosing in an elderly patient vs Schnider?

Marsh doesn't incorporate age as a covariate; Schnider adjusts clearance/compartment volumes for age, better reflecting genuine reduced elimination in the elderly.

Q. Why is Schnider's fixed V1 advantageous in obese patients?

Marsh's V1 scales with total body weight (including adipose tissue), overestimating the initial bolus; Schnider's fixed V1 plus LBM-based scaling more accurately reflects the pharmacokinetically relevant distribution volume.

★ Examiner's Pearl

State explicitly: Marsh uses total body weight with no age adjustment; Schnider uses lean body mass plus age with a fixed central compartment volume. Connect to a practical elderly/obese scenario.

References

Marsh B et al. Br J Anaesth 1991;67:41-48. Schnider TW et al. Anesthesiology 1999;90:1502-1516.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 177 person Asked by .

bookmark_add

Role of perioperative GDFT in major abdominal surgery; comparison of static versus dynamic hemodynamic parameters for assessing fluid responsiveness using advanced monitors.

description Clinical Response

"

Q25 · PAPER IV · 10 MARKS

Goal-Directed Fluid Therapy — Static vs Dynamic Hemodynamic Parameters

PGIMER · PAPER IV — RECENT ADVANCES, TECHNOLOGY & EQUIPMENT [10 MARKS]

Role of perioperative GDFT in major abdominal surgery; comparison of static versus dynamic hemodynamic parameters for assessing fluid responsiveness using advanced monitors.

⚙ Core Concept

GDFT is built on the insight that only about 50% of hemodynamically unstable patients are actually fluid-responsive. Dynamic parameters, exploiting heart-lung interactions during PPV, are far superior to static parameters at predicting responders.

A. The Role of GDFT in Major Abdominal SurgeryHigh-Yield

Traditional fixed-volume regimens caused under- or over-resuscitation. GDFT titrates fluid/vasoactive therapy to real-time hemodynamic data. Evidence shows reduced complications (SSI, anastomotic leak, ileus, AKI) and reduced LOS, especially within ERAS protocols and in high-risk populations.

Algorithm: give a bolus (~250 mL over 5-10 min) only when a validated trigger is present -> reassess SV -> if SV rises >=10-15%, responder, may repeat; if not, withhold and consider vasopressor/inotrope.

B. Static Hemodynamic Parameters3 marks

Parameter	Limitation
CVP	Poor correlation with volume status/responsiveness
PCWP	Same fundamental limitation as CVP; invasive
Heart rate, blood pressure	Influenced by many non-volume factors
Urine output	Delayed, influenced by anesthetic/stress response

The Fundamental Problem with Static Parameters

A single pressure/volume snapshot cannot indicate where the patient sits on the Frank-Starling curve; two patients with identical CVP can have opposite fluid responsiveness.

C. Dynamic Hemodynamic ParametersHigh-Yield

Parameter	Measurement	Threshold
Pulse Pressure Variation (PPV)	Arterial line waveform	> 13% suggests responsiveness
Stroke Volume Variation (SVV)	Arterial waveform analysis (FloTrac etc.)	> 10-13%
IVC distensibility/collapsibility	Ultrasound	~12-18% (technique-dependent)
Plethysmographic Variability Index (PVI)	Pulse oximeter waveform (non-invasive)	> 13-14%
Passive leg raise (PLR)	Functional ~300 mL auto-bolus test	>=10-15% rise in SV/CO

Validity Requirements — Frequently Tested

PPV/SVV are only valid with: controlled ventilation (no spontaneous effort), tidal volume >=8 mL/kg, sinus rhythm, closed chest/abdomen, no significant RV dysfunction. Given lung-protective ventilation and arrhythmia are common, PLR is increasingly favored as a broadly applicable alternative.

💬 Viva Corner

Q. Why is CVP a poor predictor of fluid responsiveness?

It is a single static pressure influenced by venous compliance, intrathoracic pressure, and RV function/compliance - it cannot indicate where on the Frank-Starling curve the patient sits.

Q. Can PPV be reliably used at Vt 6 mL/kg (lung-protective ventilation)?

No - PPV/SVV need Vt >=8 mL/kg for a reliable intrathoracic pressure swing; a passive leg raise test would be more appropriate here.

★ Examiner's Pearl

State explicitly that only ~50% of unstable patients are fluid-responsive - this justifies GDFT entirely. List the full PPV/SVV validity prerequisites and name passive leg raise as the solution when unmet.

References

Marik PE et al. Crit Care Med 2009;37:2642-2647. Pearse RM et al. JAMA 2014;311:2181-2190 (OPTIMISE).

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 178 person Asked by .

bookmark_add

Oxygen Transport & Delivery — DO₂ and VO₂

description Clinical Response

PHYSIOLOGY

1	DO₂ (oxygen delivery) = CO × CaO₂ × 10, where CaO₂ = (Hb × 1.34 × SaO₂) + (PaO₂ × 0.0031). Normal DO₂ is ~1000 mL/min. Under normal conditions, VO₂ (oxygen consumption, ~250 mL/min) is supply-independent — the body extracts only what it needs (~25%), keeping venous saturation (SvO₂) at ~75%.
2	Oxygen Extraction Ratio (OER) = VO₂/DO₂ = (SaO₂ − SvO₂)/SaO₂. Normal OER ≈ 0.25. When DO₂ falls critically below a threshold (critical DO₂ ≈ 330 mL/min/m²), VO₂ becomes supply-dependent — the tissues extract maximally, SvO₂ falls below 50%, and anaerobic metabolism with lactic acidosis ensues. This point is called the anaerobic threshold.
3	The three determinants of DO₂ are cardiac output (most manipulable), haemoglobin concentration, and SaO₂. In anaemia, the body compensates by increasing CO and OER. Marino's teaching: targeting supranormal DO₂ (DO₂I >600 mL/min/m²) does NOT improve outcomes in unselected ICU patients — the EGDT revision trials confirmed this — but maintaining adequate DO₂ in the context of shock remains essential.
4	ScvO₂ (central venous O₂ saturation) from the superior vena cava (SVC) approximates SvO₂ but runs 2–5% higher. ScvO₂ <70% signals inadequate DO₂ or elevated VO₂ and is a trigger for intervention in septic shock per the original Rivers protocol. Lactate clearance ≥10% at 2 hours is an equivalent resuscitation target endorsed by Surviving Sepsis 2021 as an alternative to ScvO₂ monitoring.
5	Fick's principle allows CO measurement: CO = VO₂ ÷ (CaO₂ − CvO₂). This is the gold-standard for CO measurement, though technically demanding. Clinically, low SvO₂ with high lactate = inadequate DO₂ to meet VO₂; high SvO₂ with high lactate = mitochondrial dysfunction or shunting (seen in late sepsis, cyanide poisoning) — a key, examinable distinction.

picture_as_pdf Clinical Reference Documents & PDFs (1)

Protected Inline Viewer

description GSehWHchCk8ouCG9zhQK8gDOtuW6yoOsRrawP1zz.pdf

open_in_new Open Full View Full View

lock Protected

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 179 person Asked by .

bookmark_add

Mechanical Ventilation — Modes & Settings

collections Question Diagrams & Reference Images (3)

zoom_in View Image

description Clinical Response

TECHNIQUE

1	Volume-Controlled Ventilation (VCV): delivers a set tidal volume (VT) regardless of lung compliance — airway pressure varies. Pressure-Controlled Ventilation (PCV): delivers a set inspiratory pressure — VT varies with compliance. In PCV, worsening compliance → falling VT (hypoventilation risk); improving compliance → rising VT (volutrauma risk). Monitoring VT is mandatory in PCV.
2	Key ventilator settings: FiO₂, VT (or Pinsp), RR, PEEP, I:E ratio, flow rate. Normal initial settings: VT 6–8 mL/kg ideal body weight (IBW), RR 12–16/min, FiO₂ 1.0 initially then titrate, PEEP 5 cmH₂O. IBW (not actual weight) must be used — using actual weight in obese patients causes dangerous volutrauma. IBW (male) = 50 + 2.3 × (height in inches − 60); IBW (female) = 45.5 + 2.3 × (height in inches − 60).
3	PEEP (Positive End-Expiratory Pressure) keeps alveoli open at end-expiration, preventing atelectasis and improving oxygenation. Intrinsic PEEP (auto-PEEP or air-trapping) occurs when exhalation is incomplete — common in COPD/obstructive disease. Detected by an end-expiratory hold manoeuvre. Auto-PEEP causes haemodynamic compromise (reduced venous return) and is managed by reducing RR, increasing expiratory time (I:E 1:3 or 1:4), or bronchodilation.
4	Pressure Support Ventilation (PSV) — patient-triggered, pressure-limited, flow-cycled. Each breath initiated by the patient; the ventilator augments inspiratory effort to a set pressure. Used for weaning. In PSV, the cycling criterion (flow drops to 25% of peak flow) allows variable inspiratory time — patients with obstructive disease may auto-cycle or have prolonged inspiration. PSV requires an intact respiratory drive.
5	Plateau pressure (Pplat) — measured by inspiratory hold; reflects alveolar/lung compliance. Target Pplat ≤30 cmH₂O (lung-protective). Driving pressure = Pplat − PEEP; target <15 cmH₂O — driving pressure is the strongest ventilator-associated predictor of mortality in ARDS (Amato 2015). Peak airway pressure reflects airway resistance + compliance; elevated peak with normal Pplat = increased resistance (secretions, bronchospasm, kinked tube).
6	High-Flow Nasal Cannula (HFNC) delivers heated, humidified O₂ at up to 60 L/min, generating low PEEP (~1 cmH₂O per 10 L/min flow) and reducing anatomical dead space. In hypoxaemic respiratory failure (non-COPD), the FLORALI trial showed HFNC reduced 90-day mortality vs face mask and NIV. The ROX index = (SpO₂/FiO₂)/RR; ROX <4.88 at 12 hours predicts HFNC failure and impending need for intubation.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 180 person Asked by .

bookmark_add

Lung-Protective Ventilation & ARDS

description Clinical Response

CRITICAL

1	Berlin Definition of ARDS (2012): Acute onset (<1 week); bilateral opacities on CXR/CT not explained by effusion or collapse; PaO₂/FiO₂ (P/F ratio) <300 on PEEP ≥5 cmH₂O; NOT fully explained by cardiac failure/fluid overload. Mild: P/F 200–300; Moderate: P/F 100–200; Severe: P/F <100. Mortality: mild ~27%, moderate ~32%, severe ~45%.
2	ARDSnet lung-protective ventilation (ARMA trial, 2000): VT 6 mL/kg IBW vs 12 mL/kg — 22% relative reduction in mortality. This is the single most impactful ventilation trial ever conducted. Pplat must be kept ≤30 cmH₂O. If Pplat exceeds 30, reduce VT to minimum 4 mL/kg IBW. Permissive hypercapnia (PaCO₂ 50–80 mmHg) is acceptable; pH ≥7.20 is the usual threshold before intervention with bicarbonate or RR increase.
3	PEEP titration in ARDS: Higher PEEP (per ARDSnet high-PEEP table or FiO₂/PEEP table) improves oxygenation by recruiting collapsed lung but can cause haemodynamic compromise and overdistension. The ALVEOLI, LOVS, and EXPRESS trials failed to show mortality benefit of high vs low PEEP strategies — optimal PEEP titration (esophageal pressure-guided, stress index, imaging-guided) remains an individualised clinical decision.
4	Prone positioning: The PROSEVA trial (2013) — 16 hours/day prone positioning in severe ARDS (P/F <150) reduced 28-day mortality from 32.8% to 16% (NNT ~6). This is one of the most striking mortality reductions ever achieved in ARDS and is now strongly recommended. Mechanism: more homogeneous ventilation-perfusion matching, reduced dorsal atelectasis. Contraindications: open abdomen, unstable spine, facial trauma.
5	Neuromuscular blockade (NMB) in ARDS: ACURASYS trial (2010) showed 48h cisatracurium infusion in moderate-severe ARDS improved survival. However, the larger ROSE trial (2019) showed NO survival benefit with routine NMB compared to light sedation strategy — NMB is now reserved for specific indications: severe dyssynchrony, refractory hypoxaemia, severe hypercapnia, prone positioning facilitation.
6	Conservative fluid strategy in ARDS (FACTT trial): once resuscitation is complete, conservative fluid management (targeting CVP 4–6, PAWP 8–12) improved ventilator-free days vs liberal strategy without increasing renal failure. Steroids in ARDS: dexamethasone 20 mg/day × 5 days then 10 mg/day × 5 days improved ventilator-free days (DEXA-ARDS trial, 2020) — particularly beneficial in inflammatory ARDS phenotype. Early, high-dose steroids remain controversial.

Emergency Medicine

General Medicine

Obstetrics & Gynaecology

Orthopedics

Pediatrics

Monthly

Quarterly

Half-Yearly (6 Months)

Yearly

Best Plan

Anesthesia

Definition, activation criteria, and viscoelastic-guided (TEG/ROTEM) resuscitation targets; metabolic/electrolyte/thermal complications; antifibrinolytics/PCC; TACO vs TRALI.

Clinical criteria and legal framework for brain death determination per THOA (India); comprehensive management of a brain-dead organ donor to optimize multiorgan yield.

Diagnosis, staging, and comprehensive ICU management of AKI following cardiac surgery; modern consensus criteria for initiating CRRT.

Architectural safety features and integrated safety mechanisms; electronic hypoxic guards, active scavenging systems, and decoupling of fresh gas flow.

Critical evaluation of depth-of-anesthesia monitoring; mathematical principles, clinical limitations, and utility in preventing intraoperative awareness.

Concept of TCI in TIVA; comparison of pharmacokinetic properties and operational differences between Marsh and Schnider models for propofol.

Role of perioperative GDFT in major abdominal surgery; comparison of static versus dynamic hemodynamic parameters for assessing fluid responsiveness using advanced monitors.

Oxygen Transport & Delivery — DO₂ and VO₂

Mechanical Ventilation — Modes & Settings

Lung-Protective Ventilation & ARDS

Subcategory Tree

Category Subscription

Anatomical Models

Case Reviews